Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with an elevated risk of premature mortality, but pharmacotherapy can significantly reduce this figure. A major new meta-analysis published in JAMA Network Open, pooling data from 16 million individuals, challenges traditional perspectives.
Researchers examined 19 observational studies conducted across three continents. The results revealed that individuals diagnosed with ADHD faced a 70% higher all-cause mortality rate compared to those without the condition. Specifically, suicide rates were 90% higher, deaths from intentional or accidental injuries were 55% higher, and natural-cause mortality was 27% higher.
Clear factors underlie these statistics: individuals with ADHD often struggle with impulse control and risk-taking behaviors, which heightens the risk of injuries, including motor vehicle accidents. This is compounded by social stigma, co-occurring mental health conditions, and barriers to accessing healthcare services. Furthermore, higher natural-cause mortality may stem from factors such as increased tobacco and alcohol use, alongside lower adherence to prescribed medical regimens.
The study’s key encouraging finding relates directly to medication: patients receiving ADHD medications demonstrated a 25% lower risk of mortality.
“ADHD is not in itself a life-limiting condition. With the right support and treatment, people with ADHD can live long, healthy lives. Our findings underline the critical importance of ensuring access to accurate diagnosis and treatment for all,” notes the study’s senior author, Professor Joshua Stott.
Despite these significant findings, the study also has limitations. The positive effect of medication was assessed in only 3 of the 19 studies. In addition, the data are observational, meaning direct causality cannot be established. Researchers emphasize that pharmacotherapy is only one piece of the puzzle and that patients require comprehensive, long-term support.
